Search Results for: ABUSE DETERRENT TECHNOLOGY New Abuse
Articles
October 29, 2016
Daiichi Sankyo & Inspirion Delivery Sciences Announce Licensing Agreement October 29, 2016
Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC recently announced the companies have entered into a strategic collaboration agreement in...
July 11, 2016
Relmada Therapeutics Secures First European Patent Covering LevoCap ER July 11, 2016
Relmada Therapeutics, Inc. recently announced it has been granted a patent from the European Patent Office (EPO) for compositions and...
January 8, 2016
SPECIAL FEATURE - Analytical Testing: Using More Sophisticated Tools to Support Small & Large Molecule Projects January 8, 2016
Contributor Cindy H. Dubin recently spoke with leading analytical testing providers to find out what services they offer and what equipment they use to handle both small and large molecules for their pharma clients.
December 16, 2015
Egalet Submits NDA for Morphine Sulfate ER Tablets December 16, 2015
Egalet Corporation recently announced the company has submitted an NDA for ARYMO ER (morphine sulfate) extended-release tablets for the management...
October 23, 2015
Elite Pharmaceuticals Announces Positive Top-Line Results October 23, 2015
Elite Pharmaceuticals, Inc. recently announced positive top-line results from the Phase III pivotal trial of its lead opioid abuse-deterrent candidate,...
December 6, 2014
Recipharm Acquires Flamel Technologies Sign Long-Term Collaboration December 6, 2014
Recipharm AB (Jordbro) and Flamel Technologies SA (Lyon) recently announced they have entered into a long-term collaboration and signed an...
September 2, 2014
EXECUTIVE INTERVIEW - Foster Delivery Science: Unmatched History & Uncompromising Focus in Hot-Melt Extrusion September 2, 2014
Drug Development Executive: Larry Acquarulo, CEO of Foster Corporation, talks about the history of Foster Delivery Science, their highly focused strategy in melt extrusion, and future plans for the business.
June 4, 2014
EXECUTIVE INTERVIEW - The Integration of Bend Research With Capsugel Dosage Form Solutions (DFS) June 4, 2014
Drug Development Executive: Rod Ray, former Bend Research CEO and now a member of Capsugel’s Scientific and Business Advisory Board, talks about the enhanced capabilities of Capsugel DFS and the advantages offered to companies developing new and/or enhanced medicines.
October 14, 2013
BioDelivery Sciences International Announces NDA Acceptance October 14, 2013
BioDelivery Sciences International, Inc. recently announced that its NDA for BUNAVAIL (buprenorphine naloxone buccal film) for the maintenance treatment of...
February 17, 2013
2/20/2013 February 17, 2013
Argos Therapeutics Announces Updated Phase II Data Argos Therapeutics Inc. recently announced updated results from its Phase II study of...
December 20, 2012
12/27/2012 December 20, 2012
Radius & 3M Announce Exclusive Agreement Radius Health, Inc. and 3M Drug Delivery Systems recently announced an exclusive partnership agreement...
May 14, 2012
5/16/2012 May 14, 2012
Mucosis Announces Positive Data for Mimopath Platform Mucosis B.V. recently announced Phase I clinical data providing proof-of-concept that Mimopath-based mucosal...
April 15, 2012
4/17/2012 April 15, 2012
Ei Increases Capabilities Through New Partnership Ei, A Pharmaceutical SolutionWorks, recently announced a new partnership with KeraNetics. Ei has begun...
April 15, 2012
QRxPharma Successfully Completes Phase I Studies April 15, 2012
QRxPharma recently announced successful completion of two Phase I studies in healthy volunteers for MoxDuo CR, a controlled-release Dual-Opioid utilizing...Issues
April 27, 2018
October 2012
COVER DRUG DEVICES – The Rise of the Bolus Injector – A New Device Class Enabling Long-Duration Subcutaneous Administration of...
